S1PR1 and myeloid sarcoma: This molecule has recently become an important target in the therapy of CNS autoimmunity, and Fingolimod (FTY720), which upon in vivo phosphorylation resembles S1P and impairs lymphocyte trafficking through the receptor subtype S1P1, has shown therapeutic efficacy in EAE [50] and, most importantly, in MS patients [51].